trabectedin

Details

Files

Generic Name:

trabectedin

Project Status:

Pending

Therapeutic Area:

Soft tissue and uterine leiomyosarcoma

Manufacturer:

N/A

Call for patient/clinician input open:

January 9, 2025

Brand Name:

N/A

Project Line:

Reimbursement Review

Project Number:

PX0377-000

Call for patient/clinician input closed:

March 3, 2025

Biosimilar:

Submission Type:

Non-sponsored Submission

Fee Schedule:

Pending

Indications:

In combination with doxorubicin for advanced unresectable or metastatic uterine or soft-tissue leiomyosarcoma.

Anticipated Date:

December 12, 2024

Last Updated : January 9, 2025